The clinical potential of HMGB1 for the risk assessment of severe checkpoint inhibitor pneumonitis: A prospective multicenter study (CS-Lung004)
Open Access
- 5 July 2025
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 226, 115606
Abstract
No abstract availableKeywords
Funding Information
- Japan Agency for Medical Research and Development
This publication has 28 references indexed in Scilit:
- Predictive role of circulatory levels of high-mobility group box 1 for radiation pneumonitis in patients with non-small cell lung cancer treated with definitive thoracic radiotherapyInternational Journal of Clinical Oncology, 2022
- Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatmentESMO Open, 2022
- The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registryEuropean Journal of Cancer, 2021
- Effect of Immune-Related Adverse Events and Pneumonitis on Prognosis in Advanced Non–Small Cell Lung Cancer: A Comprehensive Systematic Review and Meta-analysisClinical Lung Cancer, 2021
- Immune Checkpoint Inhibitor-Related Pneumonitis in Lung CancerChest, 2021
- Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort studyEuropean Journal of Cancer, 2021
- Comparison of the toxicity profile of PD‐1 versus PD‐L1 inhibitors in non–small cell lung cancer: A systematic analysis of the literatureCancer, 2017
- Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung CancerChest, 2017
- New high mobility group box 1 assay systemClinica Chimica Acta, 2006
- Promotion of cell adherence and spreading: a novel function of RAGE, the highly selective differentiation marker of human alveolar epithelial type I cellsCell and tissue research, 2005